Good afternoon :)
Place Order
Add to Watchlist

Cipla Ltd

CIPLA

Cipla Ltd

CIPLA
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,28,872 cr, stock is ranked 72
Low RiskStock is 1.83x as volatile as Nifty
1,595.751.43% (-23.15)
1,595.751.43% (-23.15)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹1,28,872 cr, stock is ranked 72
Low RiskStock is 1.83x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹1,28,872 cr, stock is ranked 72
Low RiskStock is 1.83x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.954.810.81%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.296.680.47%

Forecast & Ratings

Detailed Forecast 
67%
Analysts have suggested that investors can buy this stock

from 33 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.51%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 7.67% to 7.03%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 21.96%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue13,998.3114,622.9815,513.3616,838.9817,476.1919,425.5822,044.2523,228.5726,520.6626,909.61
Raw Materialssubtract5,026.315,206.165,671.365,737.456,236.187,544.609,220.298,348.288,756.5419,821.02
Power & Fuel Costsubtract245.92251.73298.82335.11327.43308.26331.03353.61364.84
Employee Costsubtract2,434.012,633.822,690.102,856.533,027.013,251.833,529.913,830.084,310.04
Selling & Administrative Expensessubtract1,904.002,157.792,353.982,734.652,895.692,417.363,141.753,502.923,829.37
Operating & Other expensessubtract1,700.191,669.001,392.591,601.361,439.691,385.111,169.701,873.682,417.07
Depreciation/Amortizationsubtract754.221,322.931,322.821,326.311,174.651,067.661,051.951,172.111,051.021,058.49
Interest & Other Itemssubtract206.63159.38114.23168.43197.36160.70106.35109.5489.8891.44
Taxes & Other Itemssubtract367.04215.78258.93551.44631.66885.19976.521,236.441,580.351,635.17
EPS16.9312.5217.5318.9719.1929.8231.2034.7251.0653.30
DPS2.002.003.003.004.005.005.008.5013.008.50
Payout ratio0.120.160.170.160.210.170.160.240.250.16

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 10PDF
Jan 25PDF
Oct 26PDF
Aug 5PDF
FY 2023

Annual report

PDF

Investor Presentation

May 12PDF
Jan 25PDF
Nov 4PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Jul 26PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Cipla Ltd31.274.810.81%
Sun Pharmaceutical Industries Ltd47.656.800.71%
Torrent Pharmaceuticals Ltd71.4517.260.80%
Mankind Pharma Ltd58.4911.68—

Price Comparison

Compare CIPLA with any stock or ETF
Compare CIPLA with any stock or ETF
CIPLA
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.56%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.98%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding30.91%17.62%7.33%27.81%16.33%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun27.42%25.49%25.74%25.73%25.83%27.81%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Cipla Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Flexi Cap Fund - Growth - Direct Plan

Growth
2.4644%4.80%-0.01%6/58 (-1)
HDFC ELSS Tax saver - Growth - Direct Plan

Growth
0.6791%5.33%0.23%11/52 (-6)
Kotak Flexicap Fund - Growth - Direct Plan

Growth
0.5176%1.26%0.07%33/61 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Cipla Ltd

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

CIPLA has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.81%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.14 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 2, 2024

Final
Final | Div/Share: ₹13.00

Dividend/Share

₹13.00

Ex DateEx Date

Aug 2, 2024

Cash Dividend

Ex DateEx DateJul 21, 2023

Final
Final | Div/Share: ₹8.50

Dividend/Share

₹8.50

Ex DateEx Date

Jul 21, 2023

Cash Dividend

Ex DateEx DateAug 8, 2022

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 8, 2022

Cash Dividend

Ex DateEx DateAug 9, 2021

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 9, 2021

Cash Dividend

Ex DateEx DateMar 19, 2020

Interim
Interim | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Mar 19, 2020

News & Opinions
Spotlight
Cipla Ltd gains for third straight session

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 1666.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.52% on the day, quoting at 25144.05. The Sensex is at 82028.18, up 0.48%. Cipla Ltd has gained around 2.11% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 2.22% in last one month and is currently quoting at 23307.95, up 1.99% on the day. The volume in the stock stood at 7.07 lakh shares today, compared to the daily average of 15.52 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1674.25, up 1.44% on the day. Cipla Ltd is up 44.27% in last one year as compared to a 27.7% jump in NIFTY and a 57.37% jump in the Nifty Pharma index.The PE of the stock is 33.36 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Cipla's UK arm inks pact to acquire 6.9124% stake in Cipla Jiangsu Pharmaceuticals

Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu Xidi Pharmaceuticals Co., (Xidi) for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. The said transaction is being carried out in terms of the existing joint venture contract between the parties and will provide Cipla EU with full control and ownership of Cipla Jiangsu. Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the company. The transaction is expected to be completed on or before 15th November 2024. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma company's consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024. The counter shed 0.17% to Rs 1,640.45 on the BSE.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Cipla to acquire JV partners' 6.91% in Cipla Jiangsu

Cipla announced that its wholly owned subsidiary in UK, Cipla (EU) has entered into a definitive agreement on 25 September 2024 for purchase of entire 6.9124% equity interest of Jiangsu Xidi Pharmaceuticals Co.(formerly known as Jiangsu Acebright Pharmaceuticals Co.) held in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu), subsidiary. Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu XiDi Pharmaceuticals Co. (Xidi), for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Cipla announces board meeting date

Cipla will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Cipla vice-chairman M.K. Hamied resigns

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma company's consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024. The scrip rose 0.37% to close at Rs 1652.40 on Tuesday, 3 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Cipla approves change in directorate

The Board of Cipla at its meeting held on 03 September 2024 has approved the change in directorate as under: - M K Hamied (DIN: 00029084), vide letter dated 3 September 2024, has resigned from the position of Vice Chairman and Non-Executive Director of the Company w.e.f. close of business hours of 29 October 2024 due to age and health. - Adil Zainulbhai (DIN: 06646490) and Abhijit Joshi (DIN: 06568584) have been appointed as Additional Directors (Non- Executive) of the Company with effect from 3 September 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Cipla Ltd spurts 1.99%, rises for fifth straight session

Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1650.7, up 1.99% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Cipla Ltd has risen around 6.89% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 10.59 lakh shares today, compared to the daily average of 14.77 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1662, up 2.16% on the day. Cipla Ltd is up 31.26% in last one year as compared to a 31.09% spurt in NIFTY and a 54% spurt in the Nifty Pharma index.The PE of the stock is 32.92 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Cipla Ltd up for five straight sessions

Cipla Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1586.85, up 0.77% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 24427.1. The Sensex is at 79938.07, up 0.29%. Cipla Ltd has added around 4.59% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has added around 6.42% in last one month and is currently quoting at 22209.55, down 0.12% on the day. The volume in the stock stood at 9.86 lakh shares today, compared to the daily average of 20.21 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1589.5, up 0.76% on the day. Cipla Ltd is up 28.43% in last one year as compared to a 25.69% gain in NIFTY and a 44.93% gain in the Nifty Pharma index.The PE of the stock is 32.02 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Cipla Ltd gains for third straight session

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 1574.65, up 1.36% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 24269.55. The Sensex is at 79387.27, down 0.1%. Cipla Ltd has gained around 4.14% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 7.67% in last one month and is currently quoting at 22036.95, up 0.88% on the day. The volume in the stock stood at 20.32 lakh shares today, compared to the daily average of 18.51 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1572.35, up 0.64% on the day. Cipla Ltd is up 24.38% in last one year as compared to a 23.62% jump in NIFTY and a 41.62% jump in the Nifty Pharma index.The PE of the stock is 31.59 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live